Company intelligence / Profile preview

St. Simeon

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

St. Simeon is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for the treatment of cancer. The company leverages its proprietary platform to discover and develop small molecule modulators of the innate immune system, specifically targeting the STING (Stimulator of Interferon Genes) pathway. Their lead programs are designed to activate the immune system within the tumor microenvironment to enhance anti-tumor responses and overcome resistance to existing therapies. By focusing on the innate immune response, St. Simeon aims to provide more effective and durable treatments for patients with various solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on St. Simeon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on St. Simeon.

Explore the full profile